Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

OncoImmunology

Volumn 3, Issue 5, 2014, Pages

  Kreutzman, Anna ^a,b   Ilander, Mette ^a,b   Porkka, Kimmo ^a,b   Vakkila, Jukka ^a,b   Mustjoki, Satu ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CML; Dasatinib; Granzyme b; Th1 immune response; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; DASATINIB; GAMMA INTERFERON; GRANZYME B; IMATINIB; NILOTINIB;

ARTICLE; CANCER CONTROL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE DIFFERENTIATION; MALE; MEMORY T LYMPHOCYTE; TH1 CELL;

EID: 84904045054     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28925     Document Type: Article

References (58)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343-56; PMID:11071626
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17; PMID:17151364; http://dx.doi.org/10.1056/NEJMoa062867
3. Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 2009; 21(Suppl 1):S43-6; PMID:19561414; http://dx.doi.org/10.1097/01.cco.0000357476.43164.6b
4. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22:1200-6; PMID:18401416; http://dx.doi.org/10.1038/leu.2008.84
5. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540-6; PMID:17715389; http://dx.doi.org/10.1182/blood-2007-03-080689
6. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542-51; PMID:16775235; http://dx.doi.org/10.1056/NEJMoa055104
7. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110:2309-15; PMID:17496201; http://dx.doi.org/10.1182/blood-2007-02-073528
8. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-41; PMID:16775234; http://dx.doi.org/10.1056/NEJMoa055229
9. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, et al.; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251-9; PMID:20525993; http://dx.doi.org/10.1056/NEJMoa0912614
10. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260-70; PMID:20525995; http://dx.doi.org/10.1056/NEJMoa1002315
11. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47:6658-61; PMID:15615512; http://dx.doi.org/10.1021/jm049486a
12. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94:1765-9; PMID:16721371; http://dx.doi.org/10.1038/sj.bjc.6603170
13. Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, et al.; Nordic CML Study Group (NCMLSG). Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 2013; 27:1520-6; PMID:23328954; http://dx.doi.org/10.1038/leu.2013.19
14. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49:615-9; PMID:18398720; http://dx.doi.org/10.1080/10428190801896103
15. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110:4055-63; PMID:17720881; http://dx.doi.org/10.1182/blood-2007-07-102061
16. Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007; 104:13283-8; PMID:17684099; http://dx.doi.org/10.1073/pnas.0702654104
17. BantscheffM, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25:1035-44; PMID:17721511; http://dx.doi.org/10.1038/nbt1328
18. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85:387-98; PMID:20662899; http://dx.doi.org/10.1111/j.1600-0609.2010.01501.x
19. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127:330-9; PMID:18395492; http://dx.doi.org/10.1016/j.clim.2008.02.006
20. Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105:2473-9; PMID:15572591; http://dx.doi.org/10.1182/blood-2004-07-2527
21. Chen J, Schmitt A, Chen B, Rojewski M, Rübeler V, Fei F, Yu Y, Yu X, Ringhoffer M, von Harsdorf S, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med 2008; 12(5B):2107-18; PMID:18194453; http://dx.doi.org/10.1111/j.1582-4934.2008.00234.x
22. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.1038/nm.2438
23. Zitvogel L, Kroemer G. Anticancer effects of imatinib via immunostimulation. Nat Med 2011; 17:1050-1; PMID:21900920; http://dx.doi.org/10.1038/nm.2429
24. Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114:379-88; PMID:15286804; http://dx.doi.org/10.1172/JCI21102
25. Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome. Oncoimmunology 2013; 2:e23080; PMID:23525357; http://dx.doi.org/10.4161/onci.23080
26. Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 2012; 120:4533-43; PMID:22936666; http://dx.doi.org/10.1182/blood-2012-02-407163
27. Poggi A, Zocchi MR. Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment. Oncoimmunology 2012; 1:214-6; PMID:22720246; http://dx.doi.org/10.4161/onci.1.2.18112
28. Yang Y, Lizée G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with immunotherapy. Oncoimmunology 2013; 2:e22730; PMID:23524978; http://dx.doi.org/10.4161/onci.22730
29. Kreutzman A, Porkka K, Mustjoki S. Immunomodulatory Effects of Tyrosine Kinase Inhibitors. International Trends in Immunity 2013; 01:22-33
30. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111:1366-77; PMID:17962511; http://dx.doi.org/10.1182/blood-2007-04-084814
31. Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14:2484-91; PMID:18413841; http://dx.doi.org/10.1158/1078-0432.CCR-07-4393
32. Seggewiss R, Price DA, Purbhoo MA. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy 2008; 10:633-41; PMID:18836918; http://dx.doi.org/10.1080/14653240802317639
33. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104:1094-9; PMID:15100154; http://dx.doi.org/10.1182/blood-2003-12-4266
34. Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, et al. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemiaassociated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother 2007; 56:849-61; PMID:17009043; http://dx.doi.org/10.1007/s00262-006-0232-9
35. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111:4415-6; PMID:18398058; http://dx.doi.org/10.1182/blood-2008-02-138701
36. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008; 36:1297-308; PMID:18619726; http://dx.doi.org/10.1016/j.exphem.2008.05.002
37. Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinibinduced large granular lymphocytosis and pleural effusion. Int J Hematol 2010; 91:799-807; PMID:20405252; http://dx.doi.org/10.1007/s12185-010-0565-1
38. Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer 2012; 131:E916-27; PMID:22419518; http://dx.doi.org/10.1002/ijc.27537
39. Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013; 27:914-24; PMID:23192016; http://dx.doi.org/10.1038/leu.2012.348
40. Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res 2011; 35:e1-3; PMID:20888043; http://dx.doi.org/10.1016/j.leukres.2010.08.022
41. Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94:135-9; PMID:19066329; http://dx.doi.org/10.3324/haematol.13151
42. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116:772-82; PMID:20413659; http://dx.doi.org/10.1182/blood-2009-12-256800
43. Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY, Kim HJ, Kim IH, Park S, Kim DH. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol 2011; 86:346-50; PMID:21442637; http://dx.doi.org/10.1002/ajh.21980
44. Ilander M, Hekim C, Mustjoki S. Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep 2014; 9:17-23; PMID:24390549; http://dx.doi.org/10.1007/s11899-013-0190-1
45. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6:1018-23; PMID:10973322; http://dx.doi.org/10.1038/79526
46. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, Gostick E, Yamada K, Melenhorst J, Childs R, et al. Functional leukemiaassociated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102:2892-900; PMID:12829610; http://dx.doi.org/10.1182/blood-2003-01-0150
47. Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price DA, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011; 25:1587-97; PMID:21647156; http://dx.doi.org/10.1038/leu.2011.135
48. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011; 6:e23022; PMID:21857985; http://dx.doi.org/10.1371/journal.pone.0023022
49. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73:975-83; PMID:18785267; http://dx.doi.org/10.1002/cyto.a.20643
50. Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJ, Hack CE. Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 1995; 100:164-72; PMID:7697916; http://dx.doi.org/10.1111/j.1365-2249.1995.tb03619.x
51. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918
52. Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22:371-83; PMID:15780993; http://dx.doi.org/10.1016/j.immuni.2005.02.003
53. Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 1990; 75:2005-16; PMID:1692492
54. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23:1398-405; PMID:19295545; http://dx.doi.org/10.1038/leu.2009.46
55. Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011; 52:668-79; PMID:21271862; http://dx.doi.org/10.3109/10428194.2010.550074
56. Ashley CW, Baecher-Allan C. Cutting Edge: Responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B. J Immunol 2009; 183:4843-7; PMID:19801510; http://dx.doi.org/10.4049/jimmunol.0900845
57. Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood 2011; 117:1555-64; PMID:21123824; http://dx.doi.org/10.1182/blood-2010-06-288621
58. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35:692-706; PMID:19733976; http://dx.doi.org/10.1016/j.ctrv.2009.08.004